BC Innovations | Feb 26, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Tumor necrosis factor receptor superfamily, member 21 (TNFRSF21; DR6); caspase-6 apoptosis-related cysteine peptidase (CASP6; MCH2); amyloid...
BC Week In Review | Aug 4, 2008
Clinical News

Anavex preclinical data

Anavex announced that neuroprotection occurred in mice that received 0.1 mg/kg of ANAVEX 1-41, a tetrahydrofuranic compound that modulates muscarinic and sigma-1 receptors. Data were presented at the International Conference on Alzheimer's Disease in Chicago....
BC Week In Review | Dec 3, 2007
Clinical News

Anavex preclinical data

In a mouse model of AD, ANAVEX 1-41 protected against amyloid beta peptide-induced memory deficits. The tetrahydrofuranic compound also blocked the expression of caspase-3 , which AVXL said it involved in apoptosis in the hippocampus. Data...
Items per page:
1 - 3 of 3